Principal Investigator
Antonio Jimenez
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20231336
Clinical Trial Summary
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Phase
Phase II
Funding Agency/Sponsor
Industrial
Disease
Leukemia
Contact Information
Phone Number
305-243-2647